Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a leading cause of death worldwide. The selection of therapeutic modalities and the prognosis of affected patients are well known to be dependent not only on the tumor burden but also on the hepatic reserve function. Antiviral treatments for chronic hepatitis related to a viral infection and an increase in cases of nonviral HCC associated with the aging of society have resulted in dramatic changes regarding the characteristics of HCC patients. With recent developments in therapeutic modalities for HCC, a more detailed assessment of hepatic function has become an important need. Studies in which the relationship of albumin-bilirubin (ALBI) grade with the prognosis of HCC patients was investigated were reviewed in order to evaluate the usefulness of newly developed ALBI and modified ALBI (mALBI) grades for HCC treatment, as those scoring methods are considered helpful for predicting the prognosis and selecting therapeutic modalities based on the expected prognosis.

Download Full-text

Clinical role of serum programmed death ligand 1 in patients with hepatocellular carcinoma: Where does it come from?

Surgery Today ◽

10.1007/s00595-019-01920-8 ◽

2019 ◽

Vol 50 (6) ◽

pp. 569-576

Author(s):

Hatem A. Elmezayen ◽

Hirohisa Okabe ◽

Yoshifumi Baba ◽

Toshihiko Yusa ◽

Rumi Itoyama ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Clinical Role ◽

Programmed Death Ligand 1 ◽

Programmed Death

Download Full-text

Upregulated expression of MTFR2 as a novel biomarker predicts poor prognosis in hepatocellular carcinoma by bioinformatics analysis

Future Oncology ◽

10.2217/fon-2020-1160 ◽

2021 ◽

Author(s):

Dan Li ◽

YanMei Ji ◽

JiaLong Guo ◽

Qiang Guo

Keyword(s):

Hepatocellular Carcinoma ◽

Poor Prognosis ◽

Bioinformatics Analysis ◽

Independent Predictor ◽

Cancer Stage ◽

Clinical Role ◽

P53 Signaling ◽

Dismal Prognosis ◽

P53 Signaling Pathway

Aim: The authors investigated the clinical role of MTFR2 in hepatocellular carcinoma (HCC) progression. Results: MTFR2 expression and methylation were abnormal in HCC tissues, and HCC patients with increased MTFR2 expression or methylation had poor or better overall survival, respectively. In addition, increased MTFR2 expression was correlated with age, grade, cancer stage and T stage. MTFR2 was an independent predictor of dismal prognosis in HCC patients. MTFR2 was involved in HCC progression by modulating the cell cycle, homologous recombination, DNA replication, p53 signaling pathway, etc. The ten hub genes were overexpressed in HCC tissues and were linked to cancer stage and dismal prognosis in HCC patients. Conclusion: MTFR2 could be a prospective biomarker of poor prognosis in individuals with HCC.

Download Full-text